Shared Decision-Making in Early-Stage EGFR-Mutated NSCLC
In this segment, Dr. Alexander Spira introduces the first patient case scenario, focusing on a 72-year-old man with resected stage IIB EGFR-mutated non‑small cell lung cancer (NSCLC) who has completed adjuvant chemotherapy and is considering further treatment.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT